Selank and Semax: Russian Nootropic Peptide Research

Origins and Development Context

Selank and Semax are two neuropeptides developed through research programs at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both compounds received approval as pharmaceutical agents in Russia and have been studied clinically within the Russian research system for decades. Outside of Russia, both are primarily encountered as research compounds, and the bulk of published literature originates from Russian-language journals, which affects accessibility and independent reproducibility of findings.

Selank: Structure and Mechanism

Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed as a stable analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by immunoglobulin cleavage and associated with immune modulation and CNS activity.

The anxiolytic properties of Selank are among its most studied attributes. Research has proposed several mechanisms including modulation of GABA-A receptor activity, influence on serotonin metabolism, and effects on the expression of BDNF (brain-derived neurotrophic factor) and IL-6 in brain tissue. Animal studies have demonstrated reduced anxiety behaviors in open-field and elevated plus-maze models. In Russian clinical studies, Selank has been examined as a treatment for generalized anxiety disorder.

Selank is notable for its metabolic stability relative to tuftsin. The additional C-terminal Pro-Gly-Pro sequence slows enzymatic degradation, extending its biological half-life while preserving the core pharmacophore.

Semax: Structure and Mechanism

Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-7 (Met-Glu-His-Phe), with a Pro-Gly-Pro sequence appended to its C-terminus to improve stability. Despite being derived from an ACTH fragment, Semax does not exhibit adrenocortical activity, as the minimal ACTH(4-7) sequence lacks the structural determinants required for corticotropin receptor activation.

The primary research focus for Semax has been neuroprotection and cognitive enhancement. Studies have reported upregulation of BDNF and nerve growth factor (NGF) in hippocampal and cortical tissue following Semax administration in rodent models. Neuroprotective effects have been examined in ischemia models, where Semax has been associated with reduced infarct volumes and improved neurological outcome measures. In Russia, Semax has been used clinically in the context of ischemic stroke and cognitive impairment.

Intranasal Administration

Both Selank and Semax are primarily studied and used via intranasal administration. Intranasal delivery offers a non-invasive route that bypasses first-pass hepatic metabolism and, for small peptides, may enable partial direct transport to the CNS along olfactory and trigeminal pathways — bypassing the blood-brain barrier to some degree. This is a pharmacologically relevant feature for neuropeptides whose CNS targets would otherwise be difficult to reach at meaningful concentrations via systemic administration.

Research Status: Russia vs. Western Literature

In Russia, both Selank and Semax hold regulatory approval and have been used in clinical practice. The published clinical evidence, while substantial within the Russian research ecosystem, consists largely of smaller trials without placebo controls meeting current Western regulatory standards. Independent replication in Western research settings is limited, and neither compound has advanced through Western regulatory pathways.

The mechanistic rationale for both compounds — BDNF modulation, GABA influence, neuroprotection — is credible and consistent with broader neuroscience literature. However, the evidence base as evaluated against modern clinical trial standards remains preliminary.

--- For research use only. Not medical advice.